Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Cohort of The Effects of Clinical Indicators, Drug Use and Genotypes on The Clinical Prognosis of COVID-19 Patients in Hubei Province

NCT05615792 is registered in ClinicalTrials.gov with Dao Wen Wang as lead sponsor.

NCT NCT05615792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05615792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Cohort of The Effects of Clinical Indicators, Drug Use and Genotypes on The Clinical Prognosis of COVID-19 Patients in Hubei Province
Lead sponsor
Dao Wen Wang
Phase
Observational
Overall status
Completed
Start date
February 1, 2020
Completion date
March 1, 2024
Enrollment
68,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

2019 novel coronavirus disease